Next Article in Journal
Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications
Previous Article in Journal
Neurotropism In Vitro and Mouse Models of Severe and Mild Infection with Clinical Strains of Enterovirus 71
Previous Article in Special Issue
Hijacking of the Ubiquitin/Proteasome Pathway by the HIV Auxiliary Proteins
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Viruses 2017, 9(11), 352; doi:10.3390/v9110352

Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors

1
Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China
2
Center for Nasopharyngeal Carcinoma Research, The University of Hong Kong, Hong Kong, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 31 October 2017 / Revised: 17 November 2017 / Accepted: 20 November 2017 / Published: 21 November 2017
(This article belongs to the Special Issue Viruses, ERAD, and the Proteasome)
View Full-Text   |   Download PDF [2336 KB, uploaded 21 November 2017]   |  

Abstract

Epstein-Barr virus (EBV) is closely associated with several lymphomas (endemic Burkitt lymphoma, Hodgkin lymphoma and nasal NK/T-cell lymphoma) and epithelial cancers (nasopharyngeal carcinoma and gastric carcinoma). To maintain its persistence in the host cells, the virus manipulates the ubiquitin-proteasome system to regulate viral lytic reactivation, modify cell cycle checkpoints, prevent apoptosis and evade immune surveillance. In this review, we aim to provide an overview of the mechanisms by which the virus manipulates the ubiquitin-proteasome system in EBV-associated lymphoid and epithelial malignancies, to evaluate the efficacy of proteasome inhibitors on the treatment of these cancers and discuss potential novel viral-targeted treatment strategies against the EBV-associated cancers. View Full-Text
Keywords: Epstein-Barr virus; proteasome inhibitor; apoptosis; cell cycle; lytic reactivation; Epstein-Barr virus nuclear antigen (EBNA)-3C Epstein-Barr virus; proteasome inhibitor; apoptosis; cell cycle; lytic reactivation; Epstein-Barr virus nuclear antigen (EBNA)-3C
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hui, K.F.; Tam, K.P.; Chiang, A.K.S. Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors. Viruses 2017, 9, 352.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top